Sensitivity and specificity of four assays to detect human T-lymphotropic virus type I or type I/II antibodies

被引:6
作者
Vrielink, H [1 ]
Reesink, HW [1 ]
Zaaijer, HL [1 ]
vanderPoel, CL [1 ]
Cuypers, HTM [1 ]
Lelie, PN [1 ]
机构
[1] NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV, CENT LAB, AMSTERDAM, NETHERLANDS
关键词
D O I
10.1046/j.1537-2995.1996.36496226150.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Assays that detect human T-lymphotropic virus type I and type II antibody (HTLV-I/II) are widely used in the routine screening of blood donors. Study Design and Methods: Four commercially available anti-HTLV-I (Fujirebio and Organon Teknika) or -HTLV-I/II assays (Murex and Ortho) were evaluated in various serum panels: A) HTLV-I-positive specimens (n = 41), confirmed by Western blot and polymerase chain reaction; B) a commercially available anti-HTLV-I/II panel; C) serial dilutions of sera from HTLV-I-positive individuals (n = 30), confirmed by immunofluorescence assay and Western blot; D) serial dilutions of HTLV-II-positive blood donors (n = 20), confirmed by Western blot and polymerase chain reaction, and E) sera from first-time blood donors (n = 1055). Results: All four assays elicited reactions in all 82 HTLV-I-positive samples in Panels A, B, and C. Of 32 HTLV-II-positive specimens in Panels B and D, 31 (96.9%) reacted in the Organon Teknika assay and all 32 reacted in the remaining tests. Probit analysis of test results in Panels C and D indicated that the Fujirebio test was the most sensitive assay, followed by Organon Teknika, Ortho, and Murex. The specificities of Fujirebio, Murex, Organon Teknika, and Ortho tests in 1055 first-time blood donors were 99.9, 100, 99.6, and 99.9 percent, respectively. Conclusion: All four studied assays for detecting HTLV-I or HTLV-I/II antibodies are appropriate as screening tests.
引用
收藏
页码:344 / 346
页数:3
相关论文
共 17 条
[1]  
ANDERSON DW, 1989, BLOOD, V74, P2585
[2]  
DODD RY, 1994, BLOOD SUPPLY RISKS P, P1
[3]  
FINNEY D J, 1971, P333
[4]   RAPID DEVELOPMENT OF MYELOPATHY AFTER HTLV-I INFECTION ACQUIRED BY TRANSFUSION DURING CARDIAC TRANSPLANTATION [J].
GOUT, O ;
BAULAC, M ;
GESSAIN, A ;
SEMAH, F ;
SAAL, F ;
PERIES, J ;
CABROL, C ;
FOUCAULTFRETZ, C ;
LAPLANE, D ;
SIGAUX, F ;
DETHE, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (06) :383-388
[5]   CHRONIC NEURODEGENERATIVE DISEASE ASSOCIATED WITH HTLV-II INFECTION [J].
HJELLE, B ;
APPENZELLER, O ;
MILLS, R ;
ALEXANDER, S ;
TORREZMARTINEZ, N ;
JAHNKE, R ;
ROSS, G .
LANCET, 1992, 339 (8794) :645-646
[6]  
HJELLE B, 1991, ARCH PATHOL LAB MED, V115, P440
[7]  
HJELLE B, 1993, BLOOD, V81, P1641
[8]   TRANSMISSION OF HTLV-II VIA BLOOD-TRANSFUSION [J].
HJELLE, B ;
MILLS, R ;
MERTZ, G ;
SWENSON, S .
VOX SANGUINIS, 1990, 59 (02) :119-122
[9]   PREVENTION OF TRANSMISSION OF HUMAN T-LYMPHOTROPIC VIRUS TYPE-1 (HTLV-1) THROUGH TRANSFUSION, BY DONOR SCREENING WITH ANTIBODY TO THE VIRUS - ONE-YEAR EXPERIENCE [J].
INABA, S ;
SATO, H ;
OKOCHI, K ;
FUKADA, K ;
TAKAKURA, F ;
TOKUNAGA, K ;
KIYOKAWA, H ;
MAEDA, Y .
TRANSFUSION, 1989, 29 (01) :7-11
[10]  
KHABBAZ RF, 1993, ANN INTERN MED, V118, P448